The US Supreme Court declined to review a Fourth Circuit ruling blocking Belmora’s use of the trademark Flanax in the US in a dispute with Bayer, reported Bloomberg.
The high court won’t consider to what extent foreign trademark owners can prevent registration or use of the same mark in the US. The decades-long dispute between Belmora, a small pharmaceutical company, and Bayer has centered on whether foreign trademark owners can protect their rights in the US.
Both companies claim trademark rights to the Flanax brand, which both use to sell painkillers that use the same key ingredient, naproxen sodium.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Prime Therapeutics Found in Violation of Antitrust Laws, Arbitrator Rules
Jan 23, 2025 by
CPI
Honda and Nissan Face Challenges in China Amid Potential Merger
Jan 23, 2025 by
CPI
Trump Criticizes EU’s Tech Crackdown, Calls It ‘A Form of Taxation’
Jan 23, 2025 by
CPI
Meta Faces Fresh Allegations of EU Law Breaches in Subscription Service Rollout
Jan 23, 2025 by
CPI
European Commission Investigates Crypto Rules for Cross-Border Stablecoins
Jan 23, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – International Criminal Enforcement
Jan 23, 2025 by
CPI
The Antitrust Division’s Recent Work to Combat International Cartels
Jan 23, 2025 by
Emma Burnham & Benjamin Christenson
Information Sharing: The New Frontier of U.S. Antitrust Enforcement
Jan 23, 2025 by
Brian P. Quinn, Casey Kovarik & Michael Tubach
The Key Role of Guidelines on Exchanges of Information Among Competitors and the Divergent Transatlantic Paths
Jan 23, 2025 by
Rosa Abrantes-Metz & Albert Metz
Leniency, Whistleblowers, and Compliance
Jan 23, 2025 by
Richard Powers, Tara O’Malley & Cory Gordon